Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

A Gilead can­cer drug whose de­vel­op­ments have es­sen­tial­ly been halt­ed not on­ly failed to im­prove sur­vival odds for blood can­cer pa­tients but al­so came with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.